AdaptHealth Corp. (AHCO) AI Stock Analysis

Headquartered in Plymouth Meeting, Pennsylvania, AdaptHealth Corp. is a provider of home medical equipment, medical supplies, and related services across the United States. The company specializes in sleep therapy offerings, including CPAP and bi-PAP equipment and services for obstructive sleep apnea. It also supplies diabetes management devices such as continuous glucose monitors and insulin pumps. In addition, AdaptHealth provides home medical equipment solutions for patients transitioning from acute care facilities, including oxygen therapy, chronic care management, wound care, urological supplies, incontinence products, ostomy care, and nutritional support. It serves beneficiaries of Medicare, Medicaid, and commercial insurance payors.

From FY2020 to FY2025, AdaptHealth achieved a 5-year revenue compound annual growth rate of 25.2%, with annual revenue moving from $2.45B in FY2021 to $3.24B in FY2025. In FY2025, revenue fell 0.5%, gross margin was 17.5%, and operating margin finished at 5.7%, yielding net income of -$70.8M. This followed net income of $90.4M in FY2024 and -$678.9M in FY2023. For the trailing twelve months ended June 30, 2026, revenue stood at $3.36B with an operating margin of 0.8% and EPS of -$1.82. However, the quarter ended June 30, 2026, registered quarterly revenue growth of 12.7% and quarterly earnings growth of 6.7%.

As of June 30, 2026, AdaptHealth held $43.3M in cash and short-term investments against $2.07B in total debt, resulting in net debt of $2.02B. Shareholders' equity was $1.38B against total assets of $4.34B, reflecting a debt-to-equity ratio of 1.50 and a current ratio of 1.12. In FY2025, the company generated $601.8M in operating cash flow and $219.4M in free cash flow, while directing $382.4M toward capital expenditures. Over 5 years, the company's share count change was -0.2%.

At a last close of $6.02 on October 16, 2026, AdaptHealth carries a market capitalization of $803.1M and an enterprise value of $2.78B. The stock trades at a forward P/E of 7.8x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio of 0.2x and EV-to-EBITDA multiple of 9.6x also sit below the peer medians of 4.1x and 12.0x, respectively. Over the trailing 1-year period, AHCO shares declined 34.1%, while the SPY S&P 500 benchmark gained 16.8%. Over 5 years, the shares dropped 76.2% versus an 83.0% gain for the benchmark.

Wall Street analysts maintain 6 Strong Buy ratings, 1 Buy rating, and zero Hold, Sell, or Strong Sell ratings on the stock. The mean price target is $8.86, representing a 47.1% upside compared to the last close of $6.02. For the fiscal year ending December 31, 2026, analysts forecast revenue of $2.88B and an EPS estimate of -$0.45. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of AdaptHealth Corp. (AHCO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AHCO income statement, AHCO balance sheet, AHCO key metrics, AHCO analyst forecast, AHCO chart. See the AHCO stock overview for the latest quote and news.